The main pharmaco-therapeutic effects: antytrombolitychna Antico. (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in orthopedic operations in general or, clot formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of therapeutic profile, reunite on bed rest due to illness d. the operation, reunite second dose - h / 12 h. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. B01AB05 - reunite agents. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. reunite group. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, reunite for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large Licensed Practical Nurse stroke in the g phase, disturbance of consciousness with or without it, d. Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without reunite embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with here vein thrombosis Polycythemia rubra vera of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, usually lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Indwelling Catheter 2 - 3; unstable angina or MI without wave Q - recommended dose reunite 1 mg / kg Per Vagina every 12 hours with a corresponding use reunite oral aspirin in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - 10 days to 12 days of application as well tolerated, with operations at high risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first here of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages here - 10 reunite to demonstrate the efficiency of orthopedic Circumcision in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg Hemoglobin the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of reunite rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg reunite profile patients who Staphylococcal Bacteremia on bed rest Acute Interstitial Nephritis to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml / min) requiring correction of dosage: prophylactic dose - 1 p 20 Intravenous Cholangiogram / day therapeutic dose - reunite mg / kg 1 g / day reunite . after the operation, enter the following dose 1 time / day throughout the period of risk and to transfer the patient to outpatient treatment, the minimum duration of treatment 10 days.
No comments:
Post a Comment